Search Results

BIOTRONIK is proud to introduce the Micro Rx™ catheter, a novel rapid exchange microcatheter developed to easily enhance guidewire support during percutaneous coronary interventions.

BIOTRONIK has been granted Breakthrough Device Designation (BDD) from the US Food and Drug Administration (FDA) for the Freesolve™ below-the-knee resorbable magnesium scaffold (BTK RMS).

BIOTRONIK announced the milestone achievement of 100,000 implanted single lead implantable cardioverter-defibrillators equipped with DX Technology enabling direct atrial sensing for atrial fibrillation detection and monitoring.

BIOTRONIK, a leader in implantable medical device technology, today announced its first US implantation of the new Amvia Edge pacemaker.

BIOTRONIK today announced U.S. Food and Drug Administration (FDA) approval of its portfolio of Amvia Edge pacemakers and cardiac resynchronization therapy pacemaker (CRT-P).

Continuing a history of commitment to furthering research in its field, four studies supported by BIOTRONIK’s real-world evidence generating research initiative, CERTITUDE, were presented at Heart Rhythm 2023 on May 20th and 21st.

BIOTRONIK, a leader in implantable medical device technology, today announced the first global implantation of its BIOMONITOR IV implantable cardiac monitor (ICM).

BIOTRONIK, a global leader in the treatment of cardiac and vascular disease is pleased to announce the first patient enrollment in BIO-CONDUCT, an FDA approved investigational device exemption (IDE) trial examining the use of the BIOTRONIK Solia S pacing lead when implanted in the left bundle branch (LBB) area, a location for which the Solia S lead is not currently approved.

BIOTRONIK announced today its partnership with AliveCor, a leading innovator in FDA-cleared personal electrocardiogram (ECG) technology and services.

BIOTRONIK’s state-of-the-art LiveSupport feature was used to remotely support two BIOMONITOR Implantable Cardiac Monitor (ICM) implants shortly after launch.